Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China Industrial Profits Slump Signals Need for More Economic Stimulus 
Platinum Surges to Record High as Supply Crunch and Policy Shift Drive Historic Rally 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Oil Prices Hold Steady in Asia as Geopolitical Tensions Support Market 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
